Haisco and Nuvectis sign licensing deal for two drugs

Haisco has signed an exclusive licensing agreement granting Nuvectis rights for two drug candidates in oncology and complement indications. Haisco will receive $40m upfront and may earn up to $1.4bn in additional milestone payments. HSK42360 is under evaluation in a Phase I clinical trial in China. Credit: Miyao / Shutterstock.com. Haisco Pharmaceutical Group has signed an exclusive licensing agreement granting US-based biotechnology company Nuvectis rights for two drug candidates in oncology and complement indications. Nuvectis secured worldwide rights, outside specified Asian territories, to develop, manufacture and commercialise Haisco’s drug candidates HSK42360 and HSK39297. LOA and PTSR Model Cobimetinib Fumarate…

Salong Debbarma · 2026-06-24

Haisco has signed an exclusive licensing agreement granting Nuvectis rights for two drug candidates in oncology and complement indications.

Source: Pharmaceutical Technology